Business Wire

TX-PANDA-BIOTECH

3.4.2024 15:01:28 CEST | Business Wire | Press release

Share
Panda Biotech Announces Commercial Operations Have Begun at Its Flagship Panda Hemp Gin

Panda Biotech™ announced today that commercial operations have officially begun at the Panda Hemp Gin, their landmark industrial hemp processing facility in Wichita Falls, Texas. The 500,000-square-foot building situated on 97 acres is the first of its kind and the largest in the Western Hemisphere, with the capacity to process 10 metric tons of industrial hemp into textile-grade fiber, hurd, short-fiber/hurd mix, and nutrient-rich micronized hurd per hour. It is a zero-waste process, utilizing every part of the industrial hemp stalk, and operates solely on 100 percent renewable energy, making it a paragon of sustainability in the industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403426324/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Panda Hemp Gin is a 500,000-square-foot building situated on 97 acres with the capacity to process 10 metric tons of industrial hemp into textile-grade fiber, hurd, short-fiber/hurd mix, and nutrient-rich micronized hurd per hour. (Photo: Business Wire)

The Panda Hemp Gin is fully operational, and production will continue to ramp up in the coming months. In February, the complex commissioning process of Panda's 600-yard-long processing line and three miles of overhead pneumatic duct lines, including each piece of equipment for decortication, refining, blending, mechanical cottonization, hurd bagging and storage, and baling, was successfully completed.

"Panda Biotech's state-of-the-art industrial hemp processing facility is a monumental achievement and a game-changer for both agriculture and industry,” said Dixie Carter, president of Panda Biotech. “As research and development in this area continue to advance, industrial hemp fiber and cellulose will help transform numerous industries with sustainable goals and challenges. Panda’s industrial hemp will play a pivotal role in satisfying significant global market demand for renewable processes and products.”

Industrial hemp is considered one of the most versatile raw materials available with an unmatched variety of potential uses. The Panda Hemp Gin will focus on providing five main product lines from hemp, including mechanically cottonized fiber, decorticated fiber, hurd (cellulose), short-fiber/hurd mix, and nutrient-rich micronized hemp dust. The innumerous applications for each product vary broadly from consumer and industrial textiles, non-wovens, paper products, bioplastics, biofuel, animal bedding, fiberglass substitute, construction materials such as hempcrete, mulch, insulation, and more.

With a commitment to traceability and processing only U.S.-grown hemp straw, as well as providing an astounding pay-to-grow program, Panda’s partnership with the American farming community is at the heart of the operation. Industrial hemp provides a multitude of benefits for producers, as it is scientifically proven to minimize CO2 emissions, absorbing more per acre than any forest or commercial crop. Additionally, hemp requires significantly less water than most major crops, provides outstanding soil remediation, and requires minimal fertilizers, pesticides, and herbicides. Panda is actively contracting with producers for its pay-to-grow program for this harvest and with farmers who may have straw or fiber from previous harvests or the 2024 growing season. Interested producers can reach out to Panda through the website at pandabiotech.com.

"The massive scale of the campus, allowing more than 22,000 pounds of baled hemp straw for processing per hour, is what makes this industrial hemp processing facility unique,” said Scott Evans, chief operating officer of Panda Biotech. “Our straw is sourced directly from our farming partners in Texas and surrounding states, and, through our decortication process, it is transformed into packaged products, ready for retail or downstream manufacturing applications, within minutes. Panda's processing equipment and infrastructure is truly best-in-class."

For more information, please visit www.pandabiotech.com and follow us at @pandabiotech on Facebook, Instagram, X, and LinkedIn.

ABOUT PANDA BIOTECH

Based in Dallas, Texas, privately-held Panda Biotech, LLC is a first-mover in the emerging U.S. industrial hemp fiber and hurd industry that is 100 percent American-owned, grown, and processed. Panda Biotech’s executive leadership has extensive experience developing, financing, constructing, and operating large-scale infrastructure facilities in clean energy. They have developed 22 projects representing approximately $12 billion in invested capital. Panda Biotech’s first project, the Panda Hemp Gin™, is in partnership with Aka-Ag, LLC, a wholly-owned subsidiary of the Southern Ute Indian Tribe Growth Fund. The facility is located in Wichita Falls, Texas. It is the largest industrial hemp processing facility of its kind in the Western Hemisphere.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240403426324/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye